natgillin/translations-raw huggingface dataset:
• a hernia of the tube that carries food to your stomach
• slabost (bruhanje) • hernija v predelu, ki prinaša hrano v vaš želodec
At baseline, 35 % of patients had a vertebral fracture and 59 % had a non-vertebral fracture.
V osnovnem stanju je imelo 35 % bolnikov vretenčni zlom in 59 % nevretenčni zlom.
The FORSTEO is designed to inject the full dose every time it is used according to the directions in the section Instructions for Use.
FORSTEO je oblikovan za injiciranje celotnega odmerka vsakič, ko je uporabljen v skladu z navodili v poglavju Navodila za uporabo.
Boehringer-Ingelheim RCV GmbH & Co KG, Dr.-Boehringer-Gasse 5-11, 1121 Vienna, Austria
Ime in naslov izdelovalca biološke učinkovine Boehringer-Ingelheim RCV GmbH & Co KG, Dr.-Boehringer-Gasse 5-11, 1121 Vienna, Avstrija
• low haemoglobin or red blood cell count (anaemia)
• nizek hemoglobin ali nizko število rdečih krvnih celic (anemija)
The embryotoxicity observed in rabbits may be related to their much greater sensitivity to the effects of PTH on blood ionised calcium compared with rodents.
Embriotoksičnost, ki so jo opazili pri kuncih je morda povezana z njihovo večjo občutljivostjo za učinke paratiroidnega hormona na ioniziran kalcij v krvi v primerjavi z glodalci.
• if you are allergic to teriparatide or any of the other ingredients of this medicine (listed in section 6).
• če ste alergični na (preobčutljivi za) teriparatid ali katerokoli sestavino tega zdravila (navedeno v poglavju 6).
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Od zdravstvenih delavcev se zahteva, da poročajo o katerem koli domnevnem neželenem učinku zdravila na nacionalni center za poročanje, ki je naveden v Prilogi V.*
However, the hyperuricemia did not result in an increase in gout, arthralgia, or urolithiasis.
Vendar pa hiperurikemija ni povzročila povišanja pojavnosti protina, artralgij ali urolitiaze.
Dosage adjustment based on age is not required.
Prilagajanje odmerka glede na starost ni potrebno.
Serum and urine calcium
Serumski in urinski kalcij
If you become dizzy (light-headed) after your injection, you should sit or lie down until you feel better.
Če po injiciranju postanete omotični (zmedeni), sedite ali se uležite, dokler se ne počutite bolje.
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
• Preobčutljivost na učinkovino ali katerokoli pomožno snov, navedeno v poglavju 6.1.
Some patients get dizzy or get a fast heartbeat after the first few doses.
Nekateri bolniki postanejo omotični ali imajo po prvih nekaj odmerkih hitrejši utrip srca.
In rare cases, serious and potentially life-threatening allergic reactions including anaphylaxis can occur.
V redkih primerih lahko pride do resnih in potencialno življenjsko nevarnih alergijskih reakcij, vključno z anafilakso.
Teriparatide did not increase the incidence of any other type of neoplasia in rats.
Teriparatid ni povečal incidenco kateregakoli drugega tipa novotvorb pri podganah.
The effect of teriparatide on human foetal development has not been studied.
Učinka teriparatida na razvoj humanega ploda niso preučevali.
Overdose experience based on post-marketing spontaneous reports In post-marketing spontaneous reports, there have been cases of medication error where the entire contents (up to 800 mcg) of the teriparatide pen have been administered as a single dose.
Izkušnje s prevelikim odmerjanjem na podlagi spontanih poročil po uvedbi zdravila na trg V spontanih poročilih po uvedbi zdravila na trg so poročali o primerih napačnega odmerjanja, ko so dali vso vsebino (do 800 mcg) peresnika s teriparatidom kot enkratni odmerek.
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 2.4 mL
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 2,4 ml
In a study of 15 healthy subjects administered digoxin daily to steady state, a single FORSTEO dose did not alter the cardiac effect of digoxin.
V študiji 15 zdravih oseb, ki so dnevno prejemali digoksin do stanja dinamičnega ravnovesja, enkratni odmerek zdravila FORSTEO ni spremenil učinka digoksina na srce.
• Patients with skeletal malignancies or bone metastases should be excluded from treatment with teriparatide.
• Bolniki s skeletnimi malignostmi ali kostnimi metastazami morajo biti izključeni iz zdravljenja s teriparatidom
437 patients (mean age 58.7 years) were enrolled in a clinical trial for men with hypogonadal (defined as low morning free testosterone or an elevated FSH or LH) or idiopathic osteoporosis.
437 bolnikov (povprečna starost 58,7 let) je bilo vključenih v klinično preskušanje za moške s hipogonadalno (definirano kot nizek jutranji prosti testosteron ali povišan FSH ali LH) ali idiopatsko osteoporozo.
Until further clinical data become available, the recommended treatment time of 24 months should not be exceeded.
Dokler ni na voljo nadaljnjih kliničnih podatkov, priporočenega časa zdravljenja 24 mesecev ne smemo preseči.
Treatment of suspected overdose should include transitory discontinuation of FORSTEO, monitoring of serum calcium, and implementation of appropriate supportive measures, such as hydration.
Zdravljenje domnevnega prevelikega odmerjanja naj vključuje prehodno ukinitev zdravila FORSTEO, spremljanje serumskih koncentracij kalcija in uporabo ustreznih podpornih ukrepov, kot je hidracija.
* Needles not included.
*Igle niso priložene.
Remember to use a new needle every time you inject to be sure your FORSTEO will work properly.
Ne pozabite uporabiti za vsako injiciranje novo iglo za zagotovitev, da vaš FORSTEO deluje pravilno.
Do not share your pen or your needles as this may risk transmission of infectious agents.
Vašega peresnika ali igel ne delite z drugimi, ker s tem tvegate prenos povzročiteljev okužb.
• Dispose of the device 28 days after first use.
• Medicinski pripomoček zavrzite 28 dni po prvi uporabi.
• The FORSTEO is not recommended for use by the blind or visually impaired persons without the assistance of a person trained in the proper use of the device.
• Injekcijskega peresnika FORSTEO ne priporočamo uporabljati slepim ali slabovidnim osebam, ki so brez pomoči ali osebe, usposobljene za pravilno uporabo medicinskega pripomočka.
Elderly patients Dosage adjustment based on age is not required (see section 5.2).
Starejši bolniki Prilagoditev odmerjanja glede na starost ni potrebna (glejte poglavje 5.2).
If you are considering stopping FORSTEO treatment, please discuss this with your doctor.
Če razmišljate o prenehanju jemanja zdravila FORSTEO, se o tem posvetujte s svojim zdravnikom.
When transient orthostatic hypotension occurred, it happened within the first several doses, was relieved by placing subjects in a reclining position, and did not preclude continued treatment.
Kadar se je pojavila prehodna ortostatska hipotenzija, ki se je pojavljala v času prvih nekaj odmerkov, so jo olajšali z namestitvijo osebe v ležeč položaj in ni preprečila nadaljnjega zdravljenja.
Before you use your new pen, please read the section Instructions for use completely.
Pred uporabo vašega novega injekcijskega peresnika, prosimo preberite poglavje Navodila za uporabo v celoti.
Experience in the younger adult population, including premenopausal women, is limited (see section 5.1).
Izkušnje pri populaciji mladih odraslih, vključno z ženskami pred menopavzo, so omejene (glejte poglavje 5.1).
However, no significant effect on fracture rates was demonstrated.
Vendar pa niso dokazali nobenega značilnega učinka na stopnjo zlomov.
Children and adolescents FORSTEO should not be used in children and adolescents (less than 18 years).
Zdravila FORSTEO se ne sme uporabljati pri otrocih in mladostnikih (mlajših od 18 let).
However, sporadic case reports have suggested that hypercalcaemia may predispose patients to digitalis toxicity.
Vendar pa so sporadična poročila o primerih bolnikov nakazala, da hiperkalciemija lahko naredi bolnike bolj dovzetne za toksičnost digitalisa.
The effects of overdose that might be expected include delayed hypercalcaemia and risk of orthostatic hypotension.
Učinki prevelikega odmerjanja, ki jih lahko pričakujemo, vključujejo podaljšano hiperkalciemijo in tveganje za ortostatsko hipotenzijo.
Avoid placing the pens close to the ice compartment of the refrigerator to prevent freezing.
Injekcijskih peresnikov ne polagajte blizu zamrzovalnega dela hladilnika, da se izognete zamrznjenju.
Check to make sure the red stripe shows.
Preverite, da zagotovite vidno rdečo črto.
1) If you have already injected, DO NOT inject yourself a second time on the same day.
1) Če ste si že injicirali, si NE injicirajte še drugič v istem dnevu.
Solution
Rešitev
Confirm dose
Preverite odmerek
The half-life of FORSTEO is approximately 1 hour when administered subcutaneously, which reflects the time required for absorption from the injection site.
Razpolovni čas zdravila FORSTEO je približno 1 ura po subkutanem dajanju, kar odraža čas, potreben za absorpcijo z mesta injiciranja.
Twenty-eight percent of patients had one or more radiographic vertebral fractures at baseline.
Osemindvajset odstotkov bolnikov je imelo v osnovi enega ali več radiografičnih zlomov vretenc.
All patients were offered 1000 mg calcium per day and at least 400 IU vitamin D per day.
Vsem bolnikom so ponudili 1000 mg kalcija dnevno in vsaj 400 i.e. vitamina D dnevno.
Independent risk factors, for example, low BMD, age, the existence of previous fracture, family history of hip fractures, high bone turnover and low body mass index should be considered in order to identify women and men at increased risk of osteoporotic fractures who could benefit from treatment.
Neodvisni dejavniki tveganja, na primer nizka mineralna gostota kosti (bone mineral density, BMD), starost, prisotnost predhodnih zlomov, družinska anamneza zlomov kolka, visoka kostna premena in nizek indeks telesne mase se upoštevajo za določitev žensk in moških s povečanim tveganjem za osteoporozne zlome, ki bi lahko imeli koristi od zdravljenja.
Each pen should be used by only one patient.
Vsak injekcijski peresnik je namenjen za uporabo pri samo enem bolniku.
• reduced kidney function, including renal failure
• zmanjšano delovanje ledvic, vključno z odpovedjo ledvic
The maximum total duration of treatment with FORSTEO should be 24 months (see section 4.4).
Najdaljše skupno trajanje zdravljenja z zdravilom FORSTEO naj bo 24 mesecev (glejte poglavje 4.4).
• Do not place the FORSTEO in water, or wash or clean it with any liquid.
• Injekcijskega peresnika FORSTEO ne potapljajte v vodo in ga ne spirajte ali čistite z nobeno tekočino.
Pharmaco-therapeutic group: Calcium homeostasis, parathyroid hormones and analogues, ATC code: H05 AA02.
Farmakoterapevtska skupina: zdravila za uravnavanje homeostaze kalcija, obščitnični hormoni in analogi, Oznaka ATC: H05AA02.
• Metabolic bone diseases (including hyperparathyroidism and Paget's disease of the bone) other than primary osteoporosis or glucorticoid-induced osteoporosis.
• Presnovne bolezni kosti (vključujoč hiperparatiroidizem in Pagetovo bolezen kosti) z izjemo primarne osteoporoze ali osteoporoze, povzročene z glukokorikoidi
If you stop taking FORSTEO
Če ste prenehali jemati zdravilo FORSTEO
If you have a bone disease, tell your doctor.
Če imate obolenje kosti, obvestite svojega zdravnika.
Red stripe
Rdeča črta
680 subjects were randomised to Forsteo and 680 subjects were randomised to oral risedronate 35 mg/week.
680 bolnic je bilo randomiziranih v skupino z zdravilom Forsteo, 680 bolnic pa je bilo randomiziranih v skupino s peroralnim rizedronatom 35 mg/teden.
The black injection button will be all the way in to show that the full dose has been injected from the FORSTEO.
Črni gumb za injiciranje bo popolnoma noter za zagotovitev, da ste si injicirali celoten odmerek iz injekcijskega peresnika FORSTEO.
This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially “sodiumfree”.
Zdravilo FORSTEO vsebuje natrij: To zdravilo vsebuje manj kot 1 mmol natrija (23 mg) na odmerek, kar v bistvu pomeni ‘brez natrija'.
There was no evidence of hypersensitivity reactions, allergic reactions, effects on serum calcium, or effects on Bone Mineral Density (BMD) response.
Dokazov preobčutljivostnih reakcij, alergijskih reakcij, učinkov na serumske koncentracije kalcija in na odzivnost mineralne gostote kosti (BMD) ni bilo.
No fatalities associated with overdose have been reported.
O smrtnem izidu, povezanim s prevelikim odmerjanjem, niso poročali.
If you experience discomfort such as redness of the skin, pain, swelling, itching, bruising or minor bleeding around the area of the injection (frequency is common), this should clear up in a few days or weeks.
Če občutite neugodje, kot so rdečica, bolečina, oteklina, srbenje, podplutbo ali manjše krvavitve okoli mesta injiciranja (pojavnost je pogosta), se to navadno izboljša v nekaj dneh ali tednih.
FORSTEO may cause small increases in urinary calcium excretion, but the incidence of hypercalciuria did not differ from that in the placebo-treated patients in clinical trials.
Zdravilo FORSTEO lahko povzroči majhna povečanja izločanja kalcija s sečem, vendar se incidenca hiperkalciurije ni razlikovala od incidence pri bolnikih, ki so v kliničnih preskušanjih prejemali placebo.
A user manual is also available to instruct patients on the correct use of the pen.
Za navodila bolnikom o pravilni uporabi injekcijskega peresnika je na voljo tudi priročnik za uporabo.
In postmenopausal women, a significant reduction in the incidence of vertebral and nonvertebral fractures but not hip fractures has been demonstrated.
Pri ženskah po menopavzi so dokazali pomembno znižanje pojavnosti vretenčnih in nevretenčnih zlomov, ne pa tudi zlomov kolka.
The most common side effects are pain in limb (frequency is very common, may affect more than 1 in 10 people) and feeling sick, headache and dizziness (frequency is common).
Najpogostejši neželeni učinki so bolečine v okončinah (pojavnost je zelo pogosta, pojavijo se lahko pri več kot 1 od 10 bolnikov) in slabost, glavobol in omotica (pojavnost je pogosta).
Inject dose
Injicirajte odmerek
Common: Sweating increased
Pogosto: povečano znojenje
Endogenous 84-amino-acid parathyroid hormone (PTH) is the primary regulator of calcium and phosphate metabolism in bone and kidney.
Endogeni paratiroidni hormon (PTH) iz 84 aminokislin je primarni regulator presnove kalcija in fosfata v kosteh in ledvicah.
The adverse reactions associated with the use of teriparatide in osteoporosis clinical trials and postmarketing exposure are summarised in the table below.
Neželeni učinki, povezani z uporabo teriparatida pri bolnikih z osteoporozo v kliničnih preskušanjih in pri izpostavljenosti po prihodu zdravila na trg, so povzeti v spodnji preglednici.
Place the pen back in the refrigerator and contact your doctor or pharmacist.
Položite peresnik nazaj v hladilnik in se obrnite na vašega zdravnika ali farmacevta.
• Do not store the FORSTEO with a needle attached as this may cause air bubbles to form in the cartridge.
• Injekcijskega peresnika FORSTEO ne shranjujte s pritrjeno iglo, ker lahko to povzroči nastanek zračnih mehurčkov v vložku zdravila.
If you use more FORSTEO than you should If, by mistake, you have used more FORSTEO than you should, contact your doctor or pharmacist.
Če ste uporabili večji odmerek zdravila FORSTEO, kot bi smeli Če ste pomotoma uporabili višji odmerek zdravila FORSTEO, kot bi smeli, pokličite svojega zdravnika ali farmacevta.
Chemical, physical and microbiological in-use stability has been demonstrated for 28 days at 2-8°C.
Pri temperaturi 2 do 8 °C so dokazali 28 dnevno kemijsko, fizikalno in mikrobiološko stabilnost med uporabo zdravila.
These patients should refrain from driving or the use of machines until symptoms have subsided.
Ti bolniki naj se, dokler simptomi ne izzvenijo, vzdržijo vožnje ali upravljanja strojev.
No metabolism or excretion studies have been performed with FORSTEO but the peripheral metabolism of parathyroid hormone is believed to occur predominantly in liver and kidney.
Za zdravilo FORSTEO niso opravili nobenih študij presnove ali izločanja, vendar za periferno presnovo paratiroidnega hormona velja, da poteka predvsem v jetrih in ledvicah.
A 24-month, randomized, double-blind, comparator-controlled Phase 4 study included 1,360 postmenopausal women with established osteoporosis.
24-mesečna, randomizirana, dvojno slepa študija 4. faze, nadzorovana s primerjalnim zdravilom je vključevala 1.360 žensk po menopavzi z dokazano osteoporozo.
Pull off paper tab.
Odstranite papirni pokrov.
INFORMATION IN BRAILLE FORSTEO
PODATKI V BRAILLOVI PISAVI FORSTEO
Because FORSTEO transiently increases serum calcium, FORSTEO should be used with caution in patients taking digitalis.
Ker zdravilo FORSTEO prehodno zviša serumsko koncentracijo kalcija, ga moramo pri bolnikih, ki jemljejo digitalis, uporabljati previdno.
• Pre-existing hypercalcaemia
• Že obstoječa hiperkalciemija
2) Remove the needle.
2) Odstranite iglo.
Rats treated with near-life time daily injections had dose-dependent exaggerated bone formation and increased incidence of osteosarcoma most probably due to an epigenetic mechanism.
Podgane, ki so skoraj ves čas življenja prejemale dnevne injekcije, so imele od odmerka odvisno povečano tvorbo kosti in povečano incidenco osteosarkomov, najverjetneje zaradi epigenetskega mehanizma.
• Check the FORSTEO label to make sure you have the correct medicine.
• Preverite nalepko injekcijskega peresnika FORSTEO za zagotovitev, da imate pravo zdravilo, ki ni pretečeno.
• If the medicine has been frozen, throw the device away and use a new FORSTEO.
• Če je zdravilo zamrznilo, ga zavrzite in uporabite nov injekcijski peresnik FORSTEO.
Therefore, if blood samples for serum calcium measurements are taken, this should be done at least 16 hours after the most recent FORSTEO injection.
Če se jemlje vzorec za določanje serumske koncentracije kalcija, mora biti le-ta vzet vsaj 16 ur po zadnji injekciji zdravila FORSTEO.
FORSTEO has been administered in single doses of up to 100 micrograms and in repeated doses of up to 60 micrograms/day for 6 weeks.
Zdravilo FORSTEO so dajali v enkratnih odmerkih do 100 mikrogramov in v večkratnih odmerkih do 60 mikrogramov dnevno 6 tednov.
• Do not transfer the medicine into a syringe.
• Zdravila ne prenašajte v injekcijsko brizgo.
Premenopausal women with glucocorticoid-induced osteoporosis should be considered at high risk for fracture if they have a prevalent fracture or a combination of risk factors that place them at high risk for fracture (e.g., low bone density [e.g., T score ≤−2], sustained high dose glucocorticoid therapy [e.g., ≥7.5 mg/day for at least 6 months], high underlying disease activity, low sex steroid levels).
Ženske pred menopavzo, ki imajo osteoporozo povzročeno z glukokortikoidi, se morajo obravnavati z visokim tveganjem za zlom, če imajo pogosto zlom ali kombinacijo dejavnikov tveganja, kar jih postavlja na mesto z visokim tveganjem za zlom (npr. nizka kostna gostota [npr. T vrednost ≤ −2], podaljšani visoki odmerki glukokortikoidne terapije [npr. ≥ 7,5 mg/dan za najmanj 6 mesecev], visoko osnovno delovanje bolezni, nizki nivoji spolnega steroida).
Relative risk (95% CI) vs. placebo
Relativno tveganje (95 % IZ) v primerjavi s placebom
The 24-month course of FORSTEO should not be repeated over a patient's lifetime.
24-mesečni postopek zdravljenja ne sme biti ponovljen v času bolnikovega življenja.
In short-term clinical studies with FORSTEO, isolated episodes of transient orthostatic hypotension were observed.
V kratkotrajnih kliničnih študijah zdravila FORSTEO so opažali osamljene epizode prehodne ortostatske hipotenzije.
Physiological actions of PTH include stimulation of bone formation by direct effects on bone forming cells (osteoblasts) indirectly increasing the intestinal absorption of calcium and increasing the tubular re-absorption of calcium and excretion of phosphate by the kidney.
Fiziološko delovanje paratiroidnega hormona vključuje stimulacijo tvorbe kosti z neposrednim učinkom na celice, ki izdelujejo kostnino (osteoblaste), posredno povečanje absorpcije kalcija iz črevesa, povišanje tubulne reabsorpcije kalcija in izločanje fosfata z ledvicami.
What FORSTEO is and what it is used for What you need to know before you use FORSTEO How to use FORSTEO
Kaj je zdravilo FORSTEO in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo FORSTEO Kako uporabljati zdravilo FORSTEO
Some patients may have experienced allergic reactions soon after injection, consisting of breathlessness, swelling of the face, rash and chest pain (frequency is rare).
Pri nekaterih bolnikih je prišlo do alergijske reakcije kmalu po injiciranju, ki je vključevala zadihanost, zatekanje obraza, izpuščaj in bolečine v prsnem košu (pojavnost je redka).
Do not try to make up for a missed dose.
Ne poskušajte nadomestiti izpuščenega odmerka.
• Unexplained elevations of alkaline phosphatase
• Nepojasnjene povišane vrednosti alkalne fosfataze
PHARMACEUTICAL FORM AND CONTENTS Solution for injection.
FARMACEVTSKA OBLIKA IN VSEBINA Raztopina za injiciranje.
FORSTEO has been evaluated in pharmacodynamic interaction studies with hydrochlorothiazide.
Zdravilo FORSTEO so vrednotili v študijah farmakodinamičnega medsebojnega delovanja s hidroklorotiazidom.
Manufactured by Lilly France, F-67640 Fegersheim, France for Eli Lilly and Company.
Izdeluje Lilly France, F-67640 Fegersheim, Francija za Eli Lilly and Company.
• heartburn (painful or burning sensation just below the breast bone)
• zgaga (boleč ali pekoč občutek tik pod prsnico)
The recommended dose is 20 micrograms given once daily by injection under the skin (subcutaneous injection) in the thigh or abdomen.
Priporočeni odmerek je 20 mikrogramov, danih enkrat dnevno z injiciranjem pod kožo (subkutano injiciranje) v stegno ali trebuh.
C. I see an air bubble in my FORSTEO.
FORSTEO vidim zračni mehurček.
In an open-label study, 503 postmenopausal women with severe osteoporosis and a fragility fracture within the previous 3 years (83 % had received previous osteoporosis therapy) were treated with FORSTEO for up to 24 months.
V odprti študiji so 503 ženske po menopavzi, ki so imele hudo osteoporozo in zlom zaradi krhkosti v zadnjih 3 letih (83 % jih je bilo predhodno zdravljenih za osteoporozo), do 24 mesecev dobivale zdravilo FORSTEO.
Red Stripe Blue Body Medicine Cartridge White Cap Paper Tab Needle
Rdeča črta Modro ohišje Vložek zdravila Bel pokrov Papirni pokrov Igla
You should take your FORSTEO injection shortly after you take the pen out of the refrigerator as described in the user manual.
Zdravilo FORSTEO si vbrizgajte kmalu po tem, ko vzamete injekcijski peresnik iz hladilnika, kot je opisano v Priročniku za uporabo.
Post-treatment management: Following treatment with FORSTEO, 1262 postmenopausal women from the pivotal trial enrolled in a post-treatment follow-up study.
Obravnava po zdravljenju: Po zdravljenju z zdravilom FORSTEO je 1262 žensk po menopavzi iz ključnega preskušanja sodelovalo v kontrolni študiji bolnikov po zdravljenju.
Each pen contains 2.4 mL of solution enough for 28 doses.
Vsak injekcijski peresnik vsebuje 2,4 ml raztopine, kar zadošča za 28 odmerkov.
In addition, no osteosarcomas have been observed in clinical trials or during the post treatment follow-up study.
Nadalje v kliničnih preskušanjih ali v času študije kontrole bolnikov po zdravljenju niso opazili nobenih osteosarkomov.
Screw on needle until firmly attached.
Privijte iglo, dokler ni čvrsto pritrjena.
The total duration of treatment with FORSTEO should not exceed 24 months.
Celotno trajanje zdravljenja z zdravilom FORSTEO ne sme biti daljše od 24 mesecev.
No needles are supplied with the product.
Izdelku niso priložene igle.
FORSTEO should not be used in paediatric patients (less than 18 years), or young adults with open epiphyses.
Zdravila FORSTEO pri pediatrični populaciji (mlajših od 18 let) ali mladih odraslih z odprtimi epifizami ne smemo uporabljati.
• Read and follow the instructions in the Information for the Patient leaflet for using the product.
• Preberite in sledite navodilom v Navodilu za uporabo glede uporabe izdelka.
What FORSTEO contains - The active substance is teriparatide.
Kaj vsebuje zdravilo FORSTEO - Učinkovina je teriparatid.
New vertebral fracture (≥1) a
Nov zlom vretenc (≥ 1)a